Overview

A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to study the benefit of adjuvant chemotherapy using gemcitabine and cisplatin in high risk NPC patients with residual EBV DNA following primary radiotherapy with or without concurrent cisplatin.

Phase:

Phase 3

Details

Lead Sponsor:

Chinese University of Hong Kong

Collaborator:

Hong Kong Nasopharyngeal Cancer Study Group Limited

Treatments:

Cisplatin
Gemcitabine